COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia

Parry, H. et al. (2022) COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia. Cancer Cell, 40(6), pp. 584-586. (doi: 10.1016/j.ccell.2022.05.001) (PMID:35588735) (PMCID:PMC9072807)

Full text not currently available from Enlighten.

Abstract

No abstract available.

Item Type:Articles (Letter)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Willett, Professor Brian and Scott, Mr Sam and Logan, Miss Nicola
Authors: Parry, H., Bruton, R., Roberts, T., McIlroy, G., Damery, S., Sylla, P., Dowell, A. C., Tut, G., Lancaster, T., Bone, D., Willett, B., Logan, N., Scott, S., Hulme, S., Jadir, A., Amin, U., Nicol, S., Stephens, C., Faustini, S., Al-Taei, S., Richter, A., Blakeway, D., Verma, K., Margielewska-Davies, S., Pearce, H., Pratt, G., Zuo, J., Paneesha, S., and Moss, P.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research
Journal Name:Cancer Cell
Publisher:Elsevier (Cell Press)
ISSN:1535-6108
ISSN (Online):1878-3686
Published Online:06 May 2022

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
301313Atypical bovine morbillivirus infections in the Serengeti ecosystemBrian WillettBiotechnology and Biological Sciences Research Council (BBSRC)BB/R004250/1III - Centre for Virus Research
302172A One Health approach to pan-valent morbillivirus vaccinesBrian WillettBiotechnology and Biological Sciences Research Council (BBSRC)BB/R019843/1III - Centre for Virus Research
172630004The factors that drive HCV evolution and development of an antibody-focused prophylactic HCV vaccine (Programme 3)John McLauchlanMedical Research Council (MRC)MC_UU_12014/1III - Centre for Virus Research